Newsfeeds - Spark Newswire

2 minute read

Taysha Gene Therapies Receives Orphan Drug Designation For TSHA-105 For The Treatment Of Epilepsy Caused By SLC13A5 Deficiency From The European Commission

Today, 7:15 PM

Designation supports unmet need for treatment options for patients with rare form of genetic epilepsy TSHA-105 is first program in Taysha's pipeline to receive designation from European Commission No approved

TSHA

1 minute read

Analyst Ratings

Analyst Ratings For Taysha Gene Therapies

By Benzinga Insights

Today, 7:15 PM

Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago

TSHA

1 minute read

Morgan Stanley Maintains Overweight on Taysha Gene Therapies, Lowers Price Target to $39

By Benzinga Newsdesk

Today, 7:15 PM

Morgan Stanley analyst Matthew Harrison maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and lowers the price target from $43 to $39.

TSHA

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 7:15 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 7:15 PM

ACRX

20 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 7:15 PM

Tuesday morning, 282 companies set new 52-week lows.

AAOI

1 minute read

Chardan Capital Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $60

By Benzinga Newsdesk

Today, 7:15 PM

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $67.5 to $60.

TSHA

8 minute read

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

By Shanthi Rexaline

Today, 7:15 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)

ABSI

1 minute read

Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development

By Vandana Singh

Today, 7:15 PM

Taysha Gene Therapies Inc (NASDAQ:TSHA) has entered into a loan and security agreement with Silicon Valley Bank (SVB), providing up to $100 million…

TSHA

1 minute read

Taysha Gene Therapies Q2 EPS $(1.09) Misses $(0.84) Estimate

By Benzinga Newsdesk

Today, 7:15 PM

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) by 29.76 percent.

TSHA